FDA Eases Copycat Drug Rules, Faster Access to Cheaper Drugs

Here’s a summary of the article, ⁢based on the provided text:

The⁤ FDA is planning to ease regulations surrounding “copycat” ⁤drugs, known as biosimilars. This change is intended to speed up⁣ access to these drugs and make them more affordable for both⁢ patients‍ and the pharmaceutical companies that produce them.

Key takeaway: The goal is to​ make cheaper alternatives to⁣ expensive medications more readily available.

Further ‍Facts: The article links to the American ⁤Cancer Society‍ for more information on ​biosimilar medicines.

Source & Date: The information comes from HealthDay, dated November 1, 2025.